Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $8.17 Consensus Target Price from Analysts

Posted by Shane Hupp on Sep 23rd, 2026

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has been given an average recommendation of “Hold” by the seven analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $7.3333.

JSPR has been the topic of several research reports. Wall Street Zen lowered shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler initiated coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th.

Read Our Latest Research Report on JSPR

Jasper Therapeutics Stock Performance

Shares of JSPR opened at $0.62 on Friday. The business has a 50-day moving average of $0.71 and a 200 day moving average of $0.77. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $2.69. The firm has a market cap of $20.73 million, a P/E ratio of -0.39 and a beta of 3.04.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, research analysts predict that Jasper Therapeutics will post -1.14 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

(Get Free Report)

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.